vs

Side-by-side financial comparison of Ibotta, Inc. (IBTA) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.

Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $88.5M, roughly 1.8× Ibotta, Inc.). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -10.0%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $20.3M).

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

IBTA vs STOK — Head-to-Head

Bigger by revenue
STOK
STOK
1.8× larger
STOK
$158.6M
$88.5M
IBTA
Growing faster (revenue YoY)
STOK
STOK
+3671.1% gap
STOK
3661.1%
-10.0%
IBTA
More free cash flow
STOK
STOK
$111.4M more FCF
STOK
$131.7M
$20.3M
IBTA

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
IBTA
IBTA
STOK
STOK
Revenue
$88.5M
$158.6M
Net Profit
$112.9M
Gross Margin
78.7%
Operating Margin
-1.9%
70.2%
Net Margin
71.2%
Revenue YoY
-10.0%
3661.1%
Net Profit YoY
528.0%
EPS (diluted)
$-0.03
$1.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBTA
IBTA
STOK
STOK
Q4 25
$88.5M
Q3 25
$83.3M
Q2 25
$86.0M
Q1 25
$84.6M
$158.6M
Q4 24
$98.4M
$22.6M
Q3 24
$98.6M
Q2 24
$87.9M
Q1 24
$82.3M
Net Profit
IBTA
IBTA
STOK
STOK
Q4 25
Q3 25
$1.5M
Q2 25
$2.5M
Q1 25
$555.0K
$112.9M
Q4 24
$-10.5M
Q3 24
$17.2M
Q2 24
$-34.0M
Q1 24
$9.3M
Gross Margin
IBTA
IBTA
STOK
STOK
Q4 25
78.7%
Q3 25
79.4%
Q2 25
79.2%
Q1 25
79.8%
Q4 24
84.6%
Q3 24
87.7%
Q2 24
86.0%
Q1 24
87.2%
Operating Margin
IBTA
IBTA
STOK
STOK
Q4 25
-1.9%
Q3 25
2.8%
Q2 25
1.4%
Q1 25
-3.3%
70.2%
Q4 24
13.2%
-60.4%
Q3 24
21.0%
Q2 24
-24.6%
Q1 24
19.3%
Net Margin
IBTA
IBTA
STOK
STOK
Q4 25
Q3 25
1.8%
Q2 25
2.9%
Q1 25
0.7%
71.2%
Q4 24
-46.4%
Q3 24
17.5%
Q2 24
-38.6%
Q1 24
11.3%
EPS (diluted)
IBTA
IBTA
STOK
STOK
Q4 25
$-0.03
Q3 25
$0.05
Q2 25
$0.08
Q1 25
$0.02
$1.90
Q4 24
$3.04
$-0.15
Q3 24
$0.51
Q2 24
$-1.32
Q1 24
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBTA
IBTA
STOK
STOK
Cash + ST InvestmentsLiquidity on hand
$186.6M
$274.8M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$287.7M
$350.1M
Total Assets
$525.9M
$406.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBTA
IBTA
STOK
STOK
Q4 25
$186.6M
Q3 25
$223.3M
Q2 25
$250.5M
Q1 25
$297.1M
$274.8M
Q4 24
$349.3M
$128.0M
Q3 24
$341.3M
Q2 24
$317.9M
Q1 24
$79.5M
Total Debt
IBTA
IBTA
STOK
STOK
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$65.3M
Stockholders' Equity
IBTA
IBTA
STOK
STOK
Q4 25
$287.7M
Q3 25
$329.6M
Q2 25
$354.1M
Q1 25
$401.3M
$350.1M
Q4 24
$457.3M
$229.0M
Q3 24
$378.0M
Q2 24
$359.7M
Q1 24
$44.1M
Total Assets
IBTA
IBTA
STOK
STOK
Q4 25
$525.9M
Q3 25
$569.4M
Q2 25
$600.8M
Q1 25
$639.3M
$406.9M
Q4 24
$678.4M
$271.6M
Q3 24
$598.3M
Q2 24
$556.0M
Q1 24
$322.1M
Debt / Equity
IBTA
IBTA
STOK
STOK
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBTA
IBTA
STOK
STOK
Operating Cash FlowLast quarter
$27.8M
$131.8M
Free Cash FlowOCF − Capex
$20.3M
$131.7M
FCF MarginFCF / Revenue
22.9%
83.0%
Capex IntensityCapex / Revenue
8.5%
0.1%
Cash ConversionOCF / Net Profit
1.17×
TTM Free Cash FlowTrailing 4 quarters
$75.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBTA
IBTA
STOK
STOK
Q4 25
$27.8M
Q3 25
$21.8M
Q2 25
$25.9M
Q1 25
$19.9M
$131.8M
Q4 24
$22.0M
$-23.2M
Q3 24
$39.5M
Q2 24
$35.0M
Q1 24
$19.4M
Free Cash Flow
IBTA
IBTA
STOK
STOK
Q4 25
$20.3M
Q3 25
$14.5M
Q2 25
$22.2M
Q1 25
$18.0M
$131.7M
Q4 24
$21.8M
$-23.2M
Q3 24
$39.2M
Q2 24
$34.8M
Q1 24
$19.2M
FCF Margin
IBTA
IBTA
STOK
STOK
Q4 25
22.9%
Q3 25
17.4%
Q2 25
25.8%
Q1 25
21.2%
83.0%
Q4 24
22.1%
-102.7%
Q3 24
39.8%
Q2 24
39.6%
Q1 24
23.3%
Capex Intensity
IBTA
IBTA
STOK
STOK
Q4 25
8.5%
Q3 25
8.7%
Q2 25
4.2%
Q1 25
2.2%
0.1%
Q4 24
0.2%
0.2%
Q3 24
0.3%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
IBTA
IBTA
STOK
STOK
Q4 25
Q3 25
14.19×
Q2 25
10.38×
Q1 25
35.78×
1.17×
Q4 24
Q3 24
2.29×
Q2 24
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

STOK
STOK

Segment breakdown not available.

Related Comparisons